Processa Pharmaceuticals, Inc. (PCSA)
Nasdaq · Healthcare · Biotechnology
$1.49−8.02%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $4.2M
- 52-week range
- $1.49 – $14.25
- 52-week change
- −82.11%
- EPS (trailing)
- −$4.33
Fiscal year to Dec 2025
- Net income
- $13.6M
- Diluted EPS
- −$10.36
From the company’s annual report on SEC EDGAR.
About Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers.
Headquarters: Vero Beach, United States · 12 employees · processapharmaceuticals.com